These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38789821)

  • 1. Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
    King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
    Am J Clin Dermatol; 2024 Jul; 25(4):689. PubMed ID: 38789821
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
    King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
    Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
    Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
    Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
    Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.
    King B; Guttman-Yassky E; Peeva E; Banerjee A; Zhu L; Zhu H; Cox LA; Vincent MS; Sinclair R
    JID Innov; 2022 Nov; 2(6):100156. PubMed ID: 36277481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
    Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
    J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.
    Winnette R; Banerjee A; Sikirica V; Peeva E; Wyrwich K
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):602-609. PubMed ID: 35000236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
    Ramírez-Marín HA; Tosti A
    Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
    Martin DA; Telliez JB; Pleasic-Williams S; Zhang Y; Tierney B; Blatnik M; Gale JD; Banfield C; Zhou Y; Lejeune A; Zwillich SH; Stevens E; Tiwari N; Kieras E; Karanam A
    J Clin Pharmacol; 2024 Jan; 64(1):67-79. PubMed ID: 37691236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.
    King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
    Immunotherapy; 2023 Oct; 15(14):1093-1103. PubMed ID: 37403610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
    Thaçi D; Tziotzios C; Ito T; Ko J; Karadağ AS; Fang H; Edwards RA; Bonfanti G; Wolk R; Tran H; Law E
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2621-2634. PubMed ID: 37707764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans.
    Bauman JN; Doran AC; Gualtieri GM; Hee B; Strelevitz T; Cerny MA; Banfield C; Plotka A; Wang X; Purohit VS; Dowty ME
    Drug Metab Dispos; 2024 Sep; 52(10):1124-1136. PubMed ID: 39111823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LITFULO
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
    King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
    J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
    Guttman-Yassky E; Del Duca E; Da Rosa JC; Bar J; Ezzedine K; Ye Z; He W; Hyde C; Hassan-Zahraee M; Yamaguchi Y; Peeva E
    J Allergy Clin Immunol; 2024 Jan; 153(1):161-172.e8. PubMed ID: 37777018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
    Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
    J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritlecitinib: First Approval.
    Blair HA
    Drugs; 2023 Sep; 83(14):1315-1321. PubMed ID: 37556041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European expert consensus statement on the systemic treatment of alopecia areata.
    Rudnicka L; Arenbergerova M; Grimalt R; Ioannides D; Katoulis AC; Lazaridou E; Olszewska M; Ovcharenko YS; Piraccini BM; Prohic A; Rakowska A; Reygagne P; Richard MA; Soares RO; Starace M; Vañó-Galvan S; Waskiel-Burnat A
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):687-694. PubMed ID: 38169088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.